Hanmi Pharm applies for U.S. approval new biologic ‘Rolontis’ in 4th quarter

Hanmi Pharm is expected to apply for commercialization approval for a new biologic developed by Hanmi Pharm(CEO Sae-Chang Kwon and Jong-Soo Woo) for the treatment of persistent neutropenia, Rolontis, in the U.S. this 4^th quarter.

In a press release, U.S. Spectrum Pharmaceuticals, a Hanmi Pharm’s Rolontis development partner, said the company affirmed a primary outcome variable that is non-infe...